Abstract:Background Colorectal carcinoma(CRC) is one of the most common malignant tumours, which main cause of death is tumour metastasis. The role of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) in cancer has not been well studied. This study reveals a new role of METTL3 in promoting CRC tumour progress through m6A modification of SOX2 (SRY-box 2) and influencing the Epithelial-Mesenchymal Transition process. Methods Western blot and Immunohistochemistry were used to detect METTL3 expression in cell lines and patient‘s tissues. The MTS assay, invasion assay, sphere formation assay was performed to detect the function of METTL3. Cell based xenograft model and PDX model revealed the clinical benefits of target METTL3 in vivo. Transcriptome sequencing and uencing were used to screen the m6A target genes, and MeRIP qPCR was used to detect the m6A level of the target gene. Results Using TCGA database, we found that METTL3 was significantly upregulated in human CRC and high expression of METTL3 in metastasis CRC was associated with poor prognosis of patients. Knockdown of METTL3 in CRC sample cell line and SW620 dramatically suppressed cellular proliferation, migration and sphere formation in vitro. METTL3 inhibition suppresses CRC tumorigenesis and metastasis in both cell models and PDX models in vivo. Mechanistically, we performed RNA-sequencing and MeRIP- sequencing in SW480 and SW620 CRC cell lines and SOX2 was identified as the target of METTL3-mediated m6A modification. The protein level, m6a modification level, and RNA stability of SOX2 was significantly decreased upon METTL3 inhibition. Comparing with the m6a-site-mutant SOX2, only the wildtype modified SOX2 promoting tumour progress through activating EMT process. The RNA and protein level of SOX2 downstream genes were dramatically diminished after METTL3 knockdown and both SOX2 and its target genes showed a positive correlation with METTL3 expression in CRC patients. Conclusions In summary, we demonstrated that METTL3, acting as an oncogene, was frequently upregulated in human CRC and contributed to CRC metastasis. METTL3 maintained SOX2 expression to activate EMT process through the m6A dependent mechanism. Thus, our findings reveal an important role of METTL3 and provide a potential target of treatment in colorectal carcinoma.

The m6A Methyltransferase METTL3 Promotes Cisplatin Resistance and Invasion in Testicular Seminoma via BCL2

METTL3 potentiates resistance to cisplatin through m<SUP>6</SUP>A modification of TFAP2C in seminoma

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

METTL3 Regulates the Malignancy of Cervical Cancer Via Post-Transcriptional Regulation of RAB2B

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

Targeting METTL3 Enhances the Chemosensitivity of Non-Small Cell Lung Cancer Cells by Decreasing ABCC2 Expression in an M6a-Ythdf1-dependent 6 A-YTHDF1-dependent Manner

Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner

YTHDC2-mediated m6A mRNA modification of Id3 suppresses cisplatin resistance in non-small cell lung cancer

Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer

METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy

The two-faced role of RNA methyltransferase METTL3 on cellular response to cisplatin in head and neck squamous cell carcinoma in vitro model

METTL3 -mediated m6A modification of circ_0000620 regulates cisplatin sensitivity and apoptosis in lung adenocarcinoma via the MiR-216b-5p/KRAS axis

SET and MYND Domain-Containing Protein 3 Inhibits Tumor Cell Sensitivity to Cisplatin

The effect of m6A methyltransferase METTL3 mediated TMEM30A regulation on tumor energy metabolism and cisplatin anti-tumor activity in oral squamous cell carcinoma

Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell.

Methyltransferase-like 3 Enhances Cell Proliferation and Cisplatin Resistance in Natural Killer/t-Cell Lymphoma Through Promoting N6-methyladenosine Modification and the Stability of Staphylococcal Nuclease and Tudor Domain-Containing Protein 1 Mrna.

METTL3‑mediated M6a Modification of Bcl‑2 Mrna Promotes Non‑small Cell Lung Cancer Progression

IDDF2018-ABS-0233 N6-adenosine Methyltransferase METTL3 Promotes Tumour Metastasis Via SOX2 MRNA M6A Modification in Colorectal Carcinoma

METTL3-mediated m6A modification promotes chemoresistance of intrahepatic cholangiocarcinoma by up-regulating NRF2 to inhibit ferroptosis in cisplatin-resistant cells

METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma

Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis